Changing Life Sciences Value Chain

Archives for April 2014 « Recent Articles

OfflinePhoto of Dr. Alan S. Louie

While the achievement of the $1000 genome will surely bring forth a tidal wave of new WGS data in the next 3-5 years, mountains of newly available data from completed clinical trials (likely via the Pfizer Clinical Cloud approach), related clinical trial transparency initiatives, and EMR data will likely be the near term focus of life science big data activities over the near term.

OfflinePhoto of Eric Newmark

With CA 2015 drug pedigree regulation now merely a distant memory and the first phase of the Drug Quality and Security Act (DQSA) set to begin in January 2015, there are plenty of pros and cons to reflect on. Unfortunately, the cons out-weigh the pros.

Viewed 701,186 times